Skip to main content
Download PDF

Design of mobile and website health application devices for drug tolerability in hereditary fructose intolerance

Orphanet Journal of Rare Diseases volume 19, Article number: 12 (2024) Cite this article

Abstract

Background

Hereditary fructose intolerance (HFI) is a rare metabolic disease caused by aldolase B deficiency. The aim of our study was to analyse excipient tolerability in patients with HFI and other related diseases and to design mobile and website health applications to facilitate the search for drugs according to their tolerance.

Results

A total of 555 excipients listed in the Spanish Medicines Agency database (July 2023) were classified as suitable for HFI patients, suitable with considerations ((glucose and glucose syrup, intravenous sucrose, oral mannitol, polydextrose, gums and carrageenans, ethanol, sulfite caramel and vanilla), not recommended (intravenous mannitol) and contraindicated (fructose, oral sucrose, invert sugar, sorbitol, maltitol, lactitol, isomaltitol, fruit syrups, honey, sucrose esters and sorbitol esters). Glucose and glucose syrup were classified as suitable with considerations due to its possible fructose content and their potential endogenous fructose production. For other related intolerances, wheat starch was contraindicated and oatmeal was not recommended in celiac disease; oral lactose and lactose-based coprocessed excipient (Cellactose®) were not recommended in lactose intolerance; and glucose, invert sugar and oral sucrose were not recommended in diabetes mellitus. The applications were named IntoMed®. Results are listed in order of tolerability (suitable drugs appear first and contraindicated drugs at the end), and they are accompanied by a note detailing their classified excipients. If a drug contains excipients within different categories, the overall classification will be the most restrictive. The apps are also able to classify substances with the same criteria if they act as active ingredients. The tools exhibited good usability (82.07 ± 13.46 points on the System Usability Scale [range: 0-100]) on a sample of HFI patients, their families and health care professionals.

Conclusions

IntoMed® is a tool for finding information about the tolerability of drugs according to excipients for patients with HFI and other related intolerances, with good usability. It is a fast and reliable system that covers the current excipient legislation and expands on it with other specific information: HFI patients should be alert for excipients such as mannitol (especially in intravenous drugs), fruit syrups, honey, sulfite caramel or vanilla. Glucose might contain or produce fructose, and special precaution is needed because of potential errors in their composition.

Introduction

Hereditary fructose intolerance (HFI) (OMIM #229,600) is a rare autosomal recessive metabolic disorder with a prevalence of 1–9 per 100,000 in Europe. It is caused by an enzymatic deficiency of aldolase B, an enzyme responsible for fructose metabolism (mainly in the liver). Following a large ingestion of fructose, these patients develop nausea, vomiting, hepatic and renal dysfunction, postprandial hypoglycaemia or even death. Moreover, chronic consumption of small amounts of fructose results in long-term effects (feeding difficulties, occasional vomiting, hepatic disorders and growth retardation) and, in some cases, even persistent symptoms, such as nonalcoholic fatty liver disease (NAFLD), hepatomegaly [1, 2] and altered kidney and vascular function, even with a fructose-restricted diet [3]. Currently, the only available treatment is the reduction of all fructose sources in the diet to less than 20–40 mg of fructose/kg/day (maximum of 1–2 g fructose/day); however, there is a lack of expert consensus [4].

In addition to foods that naturally contain fructose (fruits, some vegetables, honey, etc.), other sugars and sweeteners should be avoided, such as sucrose (fructose and glucose disaccharide), sorbitol (sorbitol dehydrogenase converts sorbitol to fructose), sweeteners containing sorbitol (such as maltitol, lactitol or isomaltitol), and tagatose (a fructose isomer that is metabolised by aldolase B) [4, 5].

In medicines, sugars and sweeteners are widely used in oral formulations (syrups, suspensions, tablets, etc.). This kind of excipient, especially sorbitol, can also be found in parenteral formulations and is mainly used as a stabiliser in protein/peptide drugs such as antibodies or vaccines. According to the current European medicines legislation [6], all excipients should appear on the labelling and package leaflet, and a warning for HFI patients is mandatory in drugs containing fructose, sorbitol, sucrose, invert sugar, isomaltitol, lactitol and maltitol. In addition, intravenous (IV) drugs with fructose and sorbitol are contraindicated in all children under two years because they may not yet be diagnosed with HFI (Table 1). On the other hand, there are other excipients, such as stabilisers, preservatives, flavours, colours, etc., that, due to their composition or metabolism, could generate uncertainty for patients, caregivers or health care professionals regarding their possible administration in HFI patients.

In this situation, it can be difficult to obtain fast, accessible and consensus information about the tolerance of different excipients in patients with HFI. In fact, the ease of finding this information is one of the demands of HFI patients regarding medication use [7]. In addition, HFI patients may have other intolerances, making it difficult to select appropriate medicines. In some studies, type 2 diabetes mellitus [8, 9] and celiac disease have been associated with several genetic and immune disorders, including HFI [10]. Other food intolerances, such as lactose intolerance, are frequent in the general population and may be present in these patients.

The potential of mobile device applications (apps) for rare diseases [11] or for food-related conditions is increasing. There are already apps that help patients identify food allergens or substances causing food intolerance, [12, 13] but there are no apps specialising in drug tolerability.

The aim of the present study was to analyse excipient tolerability in HFI patients and to design a mobile and website health application to allow patients with HFI and other related intolerances to identify and classify drugs according to tolerability.

Table 1 Information about drug excipients contraindicated in HFI patients from labelling and package leaflets (EMA/CHMP/302,620/2017).
Full size table

Methods

The study was developed in two phases. First, excipient tolerability in patients with HFI and other intolerances was analysed, and second, the mobile device application and website functionalities were designed. Then, their usability was evaluated.

Excipient classification

All excipients listed in the Spanish Medicines Agency database [14] in July 2023 were analysed. The database includes all authorised and marketed medicines in Spain and their technical information, including excipients with a known action or effect.

All excipients were classified into four categories according to their tolerance and the administration route (parenteral, oral and topical).

In HFI patients, the four groups were as follows:

  • Suitable: excipients that are eliminated unaltered, metabolised by a route other than aldolase B and/or those without fructose, sucrose or sorbitol in their composition.

  • Suitable with some considerations: excipients suitable for HFI patients, although some caution should be exercised.

  • Not recommended: excipients with an unknown metabolism or composition or lack of expert consensus about their tolerance in HFI patients.

  • Contraindicated: excipients that contain fructose, sucrose or sorbitol or are metabolised into these compounds.

The current European legislation was used to classify the list of excipients for celiac disease, lactose intolerance and diabetes mellitus [6] using the same classifications as those for HFI.

Application design and usability

Both the website and mobile device app were designed by a multidisciplinary team composed of hospital pharmacists with experience in HFI management, software engineers, HFI patients and HFI family members, who defined the contents and utilities. All the medicines marketed as of July 23 that appeared in the Spanish Medicines Agency database were classified into four categories according to the tolerability of the excipients with a colour and face scale: suitable (green), suitable with considerations (blue), not recommended (orange) and contraindicated (red). If a drug contained excipients with different categories, the overall classification was the most restrictive. If a new excipient appears in the Spanish Medicine Agency database, the drug will be unclassified until a pharmacist reviews the tolerability of its excipients.

After the functional requirements were designed, the apps were developed by the informatics company. Before the apps were launched, usability was evaluated with a validated Spanish version of the System Usability Scale (SUS) for the assessment of electronic tools [15]. The evaluation was carried out in a sample of HFI patients or their family members through the Spanish HFI association and health care professionals not directly related to the tool design. The SUS is a Likert-type 10-item questionnaire with positive and negative questions each scored from 1 to 5 (from strongly disagree to strongly agree, respectively). The score contribution for the positive questions is the scale position minus 1, and the contribution for the negative questions is 5 minus the scale position; the overall score was calculated from the sum of all item scores multiplied by 2.5 (range: 0 to 100). Tools with a score between 68 and 84 points are considered to have good usability, and those with a score above 85 have excellent usability [15, 16].

Results

Excipient classification

A total of 555 excipients were listed in the Spanish Medicines Agency database as of July 2023. First, the excipients were classified into four categories: suitable, suitable with some considerations (Table 2), not recommended (Table 3) and contraindicated (Table 4) in HFI patients.

Table 2 Suitable excipients with some considerations for HFI patients
Full size table
Table 3 Excipients not recommended for HFI patients
Full size table
Table 4 Contraindicated excipients in HFI patients
Full size table

Some excipients classified as suitable in HFI were galactose and lactose, glucose starches (glucose polysaccharides), artificial sweeteners (aspartame, acesulfame, cyclamate and saccharin), nonsorbitol polyalcohols (xylitol), glycerol esters, propylene glycol esters, polysorbates (tweens), gelatines, colouring agents, waxes, vegetable oils, acids, alcohols, proteins, fatty acids, ions, and salts.

Glucose syrup was classified as a suitable excipient in HFI with some considerations because although it is a suitable sweetener, it may contain fructose and also due to its potential endogenous metabolism into fructose [21]. In the first revision, corn syrup was considered a contraindicated excipient because the term was used to refer to high-fructose corn syrup (HFCS), but this was corrected in later versions of the Spanish Medicines Agency database due to our intervention with this Agency [33]. Other mistakes were corrected, such as hydrogenated starch (maltitol, sorbitol synonymous) and glucose-fructose syrup, which were both classified in the first list as contraindicated when they were labelled “pregelatinised starch” and “glucose syrup” respectively.

Furthermore, when active ingredients were the same compound as excipients, the apps classified them with the same criteria. For example, in HFI, intravenous mannitol was classified as not recommended, and lactitol was classified as contraindicated, while glucose was classified as not recommended in diabetes mellitus. Furthermore, sucrose and isomaltitol irons were classified as suitable with considerations (suitable*) for HFI patients due to their unknown metabolism.

For the other related intolerances analysed, the classification was as follows: wheat starch was contraindicated and oatmeal was not recommended in celiac disease; oral lactose and lactose-based coprocessed excipient (Cellactose®) were contraindicated in lactose intolerance; and glucose, invert sugar and oral sucrose were classified as not recommended in diabetes mellitus, while some other monosaccharides were suitable with considerations (galactose, lactose).

Application design and usability

The mobile app was named IntoMed® (available for Android® and iOS®), and the website was located at https://checkmedicine.fiibhuilhuse.es/. These tools allow users to search for drugs through several methods: intolerance selection (one or more intolerances can be selected), searcher (search can be made by active ingredient, trademark name, national drug code or excipient) and route of administration (all routes, oral, parenteral or topical). The results are shown in order of tolerability (suitable drugs appear first and contraindicated drugs at the end), and a note is displayed detailing the classified excipients (except those classified as suitable) (Fig. 1). The mobile version allows intolerances and favourite drugs to be stored. In addition, an information section shows the national drug code, anatomical therapeutic chemical classification, need for medical prescription, and generic or nongeneric drugs, and the Spanish labelling and package leaflet can also be downloaded. A help section is included where the methodology used to classify medicines according to their excipients is explained. Legal, privacy, cookies and data protection policies (apps do not collect personal data) according to current legislation were also included.

Fig. 1
figure 1

Example of results screen of IntoMed® applications

Full size image

The update of the apps with the Spanish Medicines Agency database shall be done at least twice a year. In the event of a major discrepancy being detected, it may be carried out at any time. Minor updates or development improvements will be carried out continuously through an annual maintenance contract with the informatics company.

The total usability result was 82.07 ± 13.46 points in 35 users (median age: 43 ± 10 years old); therefore, the tool is considered to have good usability. Among 12 health professionals, the result was 74.38 ± 13.94 points (median age: 42 ± 11.07 years old), and in patients and family members, it was 86.09 ± 11.55 points (median age: 44 ± 9.5 years old). Comments about usability were used to improve the experience before the apps were launched.

Discussion

The IntoMed® tools designed in this study provide, in a fast and accessible way, reliable information about the tolerability of different drugs according to their excipient content in patients with HFI and other related intolerances. Despite the progress in drug labelling, questions related to drug and sweetener tolerance (which in many cases are also excipients) are still frequent in HFI patients and their families [34].

European medicine legislation contraindicates fructose, sucrose, invert sugar, sorbitol, maltitol, lactitol and isomaltitol because they can have serious or even fatal consequences if they are administered to HFI patients. In the last legislation update [6], it was established that a warning for oral or parenteral (not intravenous) products with fructose and sorbitol at dosages of less than 5 mg/kg/day did not need to be included. This means that an oral drug with less than 5 mg/kg/day of fructose or sorbitol will not have a warning, while a drug with the same amount of contraindicated polyalcohols will, which is inconsistent considering polyalcohol metabolism. Polyalcohols undergo incomplete hydrolysis by disaccharidases in the gastrointestinal tract; for example, partial hydrolysis occurs in approximately 40% of maltitol (and sorbitol is partially absorbed), approximately 10% of isomaltitol and approximately 2% of lactitol [5, 23]. Although these polyalcohols are not permitted in HFI patients, the total absorbed fructose (sorbitol) would be less than the amount of fructose that is currently allowed by the legislation. The Italian Health Institute has been more restrictive, and it has established a fructose or sorbitol threshold of 2.4 mg/kg/dose for parenteral products and vaccines in HFI patients [35]. For this reason, the apps include any difference in the classifications of parenteral non-IV and IV drugs, as well as to simplify searches for users. Mannitol is not considered a contraindicated polyalcohol in the legislation; however, it has been classified as not recommended in this review. This decision is derived from its unknown metabolism. Mannitol, a fructose polyalcohol, is metabolised in the liver at approximately 7–10% and can be transformed into fructose or into CO2 by an unknown metabolic pathway [23, 24]. In 10% or 20% intravenous mannitol solutions, the amount provided is very high, 50–100 g/500 ml, respectively, and the consequences of its administration are unknown, which is the reason for its not recommended classification.

On the other hand, intravenous sucrose is not contraindicated because after its administration, the blood glucose concentration does not increase, and it is mainly excreted in the urine as a disaccharide [26] (because there is no disaccharidase activity outside the gut). The absence of this enzymatic activity outside the gut explains why there is no warning for parenteral sucrose formulations in the current legislation, but there are doubts about its tolerability among some health care professionals [35,36,37].

Glucose has always been the recommended sweetener in HFI patients. However, a recent study in aldolase B knockout mice has demonstrated that high glucose consumption in these mice can activate the polyol pathway and produce fructose from glucose (glucose to sorbitol by aldolase reductase, and sorbitol to fructose by sorbitol dehydrogenase), resulting in liver alterations and growth delay [21]. Further studies in humans with HFI are needed to understand the implications and consequences of fructose consumption, establishing recommended limits and/or contraindications. For this reason, glucose and its derivatives have been designated as “suitable with considerations”, but these recommendations will be updated as more evidence becomes available.

Serious errors in some sweetener definitions have been found in technical data sheets, especially in glucose derivatives. Hydrogenated starches (a synonym for polyalcohols) are obtained by a partial transformation of glucose into sorbitol, and there has been confusion between starch (suitable) and hydrogenated starch (contraindicated). On the other hand, pregelatinised or modified starch has been confused with hydrogenated starch, but in modified starch, part of its glucose chains are broken to obtain variations in its viscosity without fructose or sorbitol content. Additionally, corn syrup should be a synonym of glucose syrup, but sometimes, to increase the sweetening power of corn syrup, part of the starch or glucose is isomerised to fructose by glucose isomerase, obtaining HFCS (glucose-fructose syrup). Some confusion might appear around the term corn syrup because it has been incorrectly used to refer to both glucose syrup and HFCS [33]. Differences between food and drug legislation in relation to glucose and fructose syrup have been found. Food legislation defines glucose syrup as glucose products with up to 5% fructose, calling them “glucose and fructose syrup” only when the fructose is greater than 5% [38]. However, drug legislation states that if the glucose syrup contains fructose, it should be indicated in the ingredient list [6], but this has not always been done.

Gums and colloidal polysaccharides were classified as suitable (with considerations) in the apps in HFI patients, although some controversy has been found concerning their composition. Gums and other colloidal polysaccharides (carrageenan type) are not hydrolysed at the gastrointestinal level, and their absorption will be minimal. However, some of them may include sugars to improve their quality, or they may have been obtained through glucose or sucrose fermentation. For this reason, it is necessary to be cautious until more information is provided [19, 20, 22, 27, 28].

In current medicine legislation, aromas and flavours can be declared in generic terms, although components with a recognised action or effect must be specifically declared [6]. Supplements are added to flavours to facilitate storage, standardisation, dilution, dissolution and/or stabilisation, and they may be sugars or polyalcohols that are contraindicated in HFI (sorbitol, isomaltitol, maltitol or lactitol) [39]. Furthermore, there are flavours that contain fructose, sucrose or sorbitol, and according to HFI dietary guidelines, they are not recommended (e.g., honey flavouring, vanillin, vanilla flavouring, liquorice extract, etc.) [4]. Even so, there are fruit juices or extracts with unknown compositions, colours obtained by mechanical methods from fruit (beet red) or sugar derivatives (caramel colour). In these cases, there is no warning for HFI patients on the labels.

Sucrose esters or sorbitol esters (spans) obtained by the partial esterification of sorbitol with fatty acids are hydrolysed by esterases and release sucrose or sorbitol [30,31,32]. Spans are usually present in topical preparations and in this case are considered suitable [40, 41], but when they are used in oral or parenteral drugs, caution is needed in HFI patients. In contrast, polysorbates (tweens) are sorbitol esters with polyoxyethylene fatty acids, but the link between sorbitol and ethylene oxide cannot be hydrolysed [30]. Despite this, polysorbate intoxication after the administration of an intravenous drug with polysorbate 80 was described in an HFI patient with hepatorenal alterations and hypoglycaemia, similar to fructose intoxication [42]. There are also studies describing liver and kidney toxicity in non-HFI patients taking drugs containing polysorbates [43], so it is possible that the alterations were caused by the toxicity of polysorbate itself rather than fructose intoxication.

There is increasing interest in electronic health (eHealth), especially in mobile technology (mHealth), in recent years, with the aim of helping patients, consumers and even health professionals. These technologies could be useful due to the lack of information on rare diseases [7, 44] and because many health professionals encounter few patients with these characteristics throughout their professional career, and therefore, they require the help of decision-making tools. These apps contain information not only about excipients with box warnings but also about some other sugars, sweeteners or excipients for which there is currently no specified legislation for HFI patients but that may produce intolerance when they are present in drugs. In addition, the possibility of selecting other diseases was included in the development of the apps, as HFI has also been linked with other pathologies, such as type 2 diabetes mellitus or glucose intolerance [8, 9] and celiac disease [10]. The usability of digital applications by potential users is a key parameter of good practice in their development. In our case, the reliability and usability of the tools were demonstrated, although the score was better in patients than in health professionals, possibly due to the problems they encountered daily. Furthermore, the sample used for this study consisted of a multidisciplinary team (included in the design), HFI patients and their families, and health professionals. The SUS is a frequently used questionnaire in eHealth and mHealth because it is an easy and quick tool [45] and is validated in Spanish [15], although it was not designed to evaluate the usability of mHealth apps.

The present study has several limitations. The information about excipient metabolism described in the literature is old and incomplete, and it is not specific for HFI patients. For this reason, in some cases, it is not possible to obtain conclusions about metabolism or composition related to fructose. Moreover, the information for classifying excipients in these apps depends on updates from the Spanish Medicine Agency, so a warning is included for users.

In conclusion, IntoMed® is a new tool for finding information about the tolerability of drugs containing excipients in patients with HFI and other related intolerances. It is a fast and reliable system that covers the current excipient legislation and expands it with other specific information. It is important to highlight that there are excipients not included in the legislation and do not appear on labels; however, due to their metabolic involvement, they should have a warning for HFI patients. These excipients include mannitol (especially in IV drugs), fruit syrups, honey, sulfite caramel and vanilla. Moreover, it is necessary to take special precautions with glucose and glucose syrups because of frequent and important errors in compounding and their potential endogenous production of fructose. Through the review carried out in this study, the deficiencies of some excipients with unclear information have been revealed. Furthermore, it has been possible to respond to these unmet needs.

Data Availability

The datasets generated and/or analyzed during the current study are not publicly available due individual privacy but are available from the corresponding author (Izquierdo-García E: elsa.izquierdo@salud.madrid.org) on reasonable request.

Abbreviations

HFI:

Hereditary Fructose Intolerance

app:

Application

IV:

Intravenous

HFCS:

High fructose corn syrup

NAFLD:

Non-alcoholic fatty liver disease

eHealth:

Electronic Health

mHealth:

Mobile Health

SUS:

System Usability Scale

References

  1. Bouteldja N, Timson DJ. The biochemical basis of hereditary fructose intolerance. J Inherit Metab Dis. 2010;33:105–12.

    Article  CAS  PubMed  Google Scholar 

  2. Aldámiz-Echevarría L, de Las Heras J, Couce ML, Alcalde C, Vitoria I, Bueno M, et al. Non-alcoholic fatty liver in hereditary fructose intolerance. Clin Nutr Edinb Scotl. 2020;39:455–9.

    Article  Google Scholar 

  3. Simons N, Debray FG, Schaper NC, Feskens EJM, Hollak CEM, Bons JAP, et al. Kidney and vascular function in adult patients with hereditary fructose intolerance. Mol Genet Metab Rep. 2020;23:100600.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. Ruiz Pons M, de Las Heras J, Aldámiz-Echevarría L. Errores congénitos del metabolismo de la fructosa. In: Couce ML, Aldámiz-Echevarría L, García-Jimenez MC, González Lamuño D, editores. Diagnóstico y tratamiento de las enfermedades metabólicas hereditarias. 5.a ed. Majadahonda (Madrid): Ergon; 2022. p. 729– 39.

  5. Izquierdo-García E, Moreno-Villares JM, León-Sanz M. Sweeteners in hereditary fructose intolerance patients. Acta Pediátrica Esp. 2014;72:15–23.

    Google Scholar 

  6. European Union. Excipients in the labelling and package leaflet of medicinal products for human use. Annex to the European Commission guideline. EMA/CHMP/302620/2017. 2017.

  7. Izquierdo-García E, Escobar-Rodríguez I, Moreno-Villares JM, Iglesias-Peinado I. Social and health care needs in patients with hereditary fructose intolerance in Spain. Endocrinol Diabetes Nutr. 2020;67:253–62.

    Article  Google Scholar 

  8. Desai JR, Hyde CL, Kabadi S, St Louis M, Bonato V, Katrina Loomis A, et al. Utilization of positive and negative controls to Examine Comorbid associations in Observational Database studies. Med Care. 2017;55:244–51.

    Article  PubMed  Google Scholar 

  9. Simons N, Debray FG, Schaper NC, Kooi ME, Feskens EJM, Hollak CEM, et al. Patients with Aldolase B Deficiency are characterized by increased intrahepatic triglyceride content. J Clin Endocrinol Metab. 2019;104:5056–64.

    Article  PubMed  Google Scholar 

  10. Ciacci C, Gennarelli D, Esposito G, Tortora R, Salvatore F, Sacchetti L. Hereditary fructose intolerance and celiac Disease: a novel genetic association. Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc. 2006;4:635–8.

    Google Scholar 

  11. Groft SC, de la Posada M. Preparing for the future of Rare Diseases. Adv Exp Med Biol. 2017;1031:641–8.

    Article  PubMed  Google Scholar 

  12. Cuervo-Pardo L, Barcena-Blanch MA, Gonzalez-Estrada A, Schroer B. Apps for food allergy: a critical assessment. J Allergy Clin Immunol Pract. 2015;3:980–981e1.

    Article  PubMed  Google Scholar 

  13. Mandracchia F, Llauradó E, Tarro L, Valls RM, Solà R. Mobile Phone Apps for Food Allergies or intolerances in App Stores: systematic search and Quality Assessment using the Mobile App Rating Scale (MARS). JMIR MHealth UHealth. 2020;8:e18339.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Agencia Española del Medicamento y Productos Sanitarios. Nomenclator de prescripción. Madrid. https://cima.aemps.es/cima/publico/nomenclator.html. Accessed 1 July 2023.

  15. Sevilla-Gonzalez MDR, Moreno Loaeza L, Lazaro-Carrera LS, Bourguet Ramirez B, Vázquez Rodríguez A, Peralta-Pedrero ML, et al. Spanish Version of the System Usability Scale for the Assessment of Electronic tools: Development and Validation. JMIR Hum Factors. 2020;7:e21161.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Brooke J. SUS - a quick and dirty usability scale. Usability Eval Ind. 1996;189(194):4–7.

    Google Scholar 

  17. Ratsimba V, García Fernández JM, Defaye J, Nigay H, Voilley A. Qualitative and quantitative evaluation of mono- and disaccharides in D-fructose, D-glucose and sucrose caramels by gas-liquid chromatography-mass spectrometry. Di-D-fructose dianhydrides as tracers of caramel authenticity. J Chromatogr A. 1999;844:283–93.

    Article  CAS  PubMed  Google Scholar 

  18. Sengar G, Sharma HK. Food caramels: a review. J Food Sci Technol. 2014;51:1686–96.

    Article  CAS  PubMed  Google Scholar 

  19. European Food Safety Authority (EFSA) Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to acacia gum (gum Arabic) and decreasing potentially pathogenic gastro-intestinal microorganisms (ID 758), changes in short chain fatty acid (SCFA) production and pH in the gastro-intestinal tract (ID 759), changes in bowel function (ID 759), reduction of gastrointestinal discomfort (ID 759), maintenance of faecal nitrogen content and/or normal blood urea concentrations (ID 840, 1975), and maintenance of normal blood LDL-cholesterol concentrations (ID 841) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011;9(4):2022.

    Article  Google Scholar 

  20. JECFA: Joint FAO/WHO Expert Committee on Food Additives., 2008. 68th Report of the Joint FAO/WHO Expert Committee on Food Additives; Evaluation of Certain Food Additives and Contaminants. WHO Technical Report Series 947, 32–37.

  21. Andres-Hernando A, Orlicky DJ, Kuwabara M, Cicerchi C, Pedler M, Petrash MJ, et al. Endogenous Fructose Production and Metabolism Drive Metabolic Dysregulation and Liver Disease in Mice with Hereditary Fructose Intolerance. Nutrients. 2023;15:4376.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. European Food Safety Authority (EFSA). Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to guar gum and maintenance of normal blood glucose concentrations (ID 794), increase in satiety (ID 795) and maintenance of normal blood cholesterol concentrations (ID 808) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2010;8(2):1464.

    Google Scholar 

  23. Livesey G. Health potential of polyols as sugar replacers, with emphasis on low glycaemic properties. Nutr Res Rev. 2003;16:163–91.

    Article  CAS  PubMed  Google Scholar 

  24. Nasrallah SM, Iber FL. Mannitol absorption and metabolism in man. Am J Med Sci. 1969;258:80–8.

    Article  CAS  PubMed  Google Scholar 

  25. Canfora EE, Blaak EE. The role of polydextrose in body weight control and glucose regulation. Curr Opin Clin Nutr Metab Care. 2015;18:395–400.

    Article  CAS  PubMed  Google Scholar 

  26. Weser E, Sleisenger MH. Metabolism of circulating disaccharides in man and the rat. J Clin Invest. 1967;46:499–505.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. European Food Safety Authority (EFSA) Panel on Food Additives and Nutrient Sources added toFood (ANS), Mortensen A, Aguilar F, Crebelli R, Domenico AD, Frutos MJ et al. Scientific Opinion on the re-evaluation of tragacanth (E 413) as afood additive. EFSA Journal. 2017;15(6):4789.

  28. European Food Safety Authority (EFSA). Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to xanthan gum and changes in bowel function (ID 837) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J. 2011;9:2272.

    Article  Google Scholar 

  29. Thomas AL, Byers PL, Gu S, Avery JD, Kaps M, Datta A, et al. Occurrence of Polyphenols, Organic Acids, and Sugars among Diverse Elderberry Genotypes Grown in Three Missouri (USA) Locations. Acta Hortic. 2015;1061:147–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. European Food Safety Authority (EFSA) Panel on Food Additives and Nutrient Sources added to Food (ANS). Scientific Opinion on the re-evaluation of polyoxyethylene sorbitan monolaurate (E 432), polyoxyethylene sorbitan monooleate (E 433), polyoxyethylene sorbitan monopalmitate (E 434), polyoxyethylene sorbitan monostearate (E 435) and polyoxyethylene sorbita: Re-evaluation of polyoxyethylene sorbitans (E 432-E 436) as food additives. EFSA J. 2015;13(7):4152.

    Google Scholar 

  31. International programme on Chemical Safety (IPCS) INCHEM. Toxicological evaluation of some food additives. No 547 Sorbitan monoesters of palmitic/stearic/oleic/lauric acids/triesters/stearic acid. WHO Food Additive Series No 17. 1982.

  32. European Food Safety Authority (EFSA) EFSA Panel on Food Additives and Nutrient Sources added to Food (ANS). Scientific Opinion on the safety of sucrose esters of fatty acids prepared from vinyl esters of fatty acids and on the extension of use of sucrose esters of fatty acids in flavourings on request from the European Commission. EFSA J. 2010;8(3):1512.

    Google Scholar 

  33. Izquierdo-García E, Escobar Rodríguez I, Moreno-Villares JM, Iglesias Peinado I. Drug syrups: Errors in drug labels with possible consequences in patients with heritary fructose intolerance. An Pediatría. 2017;87:351–3.

    Article  Google Scholar 

  34. Izquierdo Garcia E, Escobar Rodríguez I, Moreno Villares JM, Iglesias Peinado I. Pharmacist as a qualified advisor in patients associations with rare diseases: experience in hereditary fructose intolerance. Eur J Clin Pharm. 2018;20:282–3.

    Google Scholar 

  35. Maiorana A, Sabia A, Corsetti T, Dionisi-Vici C. Safety of vaccines administration in hereditary fructose intolerance. Orphanet J Rare Dis. 2020;15:274.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Izquierdo-Garcia E, Alvaro Alonso EA, Montero Pastor B, Such Díaz A. Escobar Rodríguez I. Reply letter to the editor concerning the article «Safety of Sars-Cov-2 vaccines administration for adult patients with hereditary fructose intolerance». Hum Vaccines Immunother. 2022;18:2051414.

    Article  Google Scholar 

  37. Saborido-Fiaño R, Martinón-Torres N, Crujeiras-Martinez V, Couce ML, Leis R. Letter to the editor concerning the article ‘Safety of vaccines administration in hereditary fructose intolerance’. Hum Vaccines Immunother. 2021;0:1–2.

    Google Scholar 

  38. The council of the European Union. Council Directive 2001/111/EC of 20 December 2001 relating to certain sugars intended for human consumption. OJ L. 2002;10(1):53–7.

    Google Scholar 

  39. The council of the European Union. Commission Regulation (EU) No 1130/2011 of 11 November 2011 amending Annex III to Regulation (EC) No 1333/2008 of the European Parliament and of the Council on food additives by establishing a Union list of food additives approved for use in food additives, food enzymes, food flavourings and nutrients Text with EEA relevance. OJ L. 2011;295(11):178–204.

    Google Scholar 

  40. European Medicines Agency. Overview of comments received on the draft «Information in the package leaflet for fructose and sorbitol» (EMA/CHMP/460886/2014). EMA/CHMP/581887/2016.

  41. European Medicines Agency. Information for the package leaflet regarding fructose and sorbitol used as excipients in medicinal products for human use. EMA/CHMP/460886/2014. 2017.

  42. Curran BJ, Havill JH. Hepatic and renal failure associated with amiodarone infusion in a patient with hereditary fructose intolerance. Crit Care Resusc J Australas Acad Crit Care Med. 2002;4:112–5.

    CAS  Google Scholar 

  43. Rhodes A, Eastwood JB, Smith SA. Early acute hepatitis with parenteral amiodarone: a toxic effect of the vehicle? Gut. 1993;34:565–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Diaz E, Huete A. Estudio sobre Situación de Necesidades Sociosanitarias de las Personas con Enfermedades Raras en España. Estudio ENSERio. Madrid: Federación Española de Enfermedades Raras (FEDER); 2009.

    Google Scholar 

  45. Maramba I, Chatterjee A, Newman C. Methods of usability testing in the development of eHealth applications: A scoping review. Int J Med Inf. 2019;126:95–104.

    Article  Google Scholar 

Download references

Acknowledgements

We thank to Spanish Association Hereditary Fructose Intolerance (http://www.aaihf.com/) for their collaboration. The mobile device application and website were developed by Meytel® informatics company (https://www.meytel.net/). Currently, the Foundation for Biomedical Research and Innovation of the Hospital Universitario Infanta Leonor and Sureste is the owner of IntoMed® (innovacion@fiibhuilhuse.es).

Funding

The first version of mobile device application and website were financed with the award of a Cinfa® contest 2019: Contigo50ymas®. The Foundation for Biomedical Research and Innovation of the Hospital Universitario Infanta Leonor and Sureste has placed the web/app into the market and is financing current developments, maintenance and application updates. Authors confirm independence from the sponsors; the content of the article has not been influenced by the sponsors. The authors have declared that no conflicts of interests exist.

Author information

Authors and Affiliations

  1. Pharmacy Department, Hospital Universitario Infanta Leonor, Av. Gran Vía del Este, 80, Madrid, 28031, Spain

    Elsa Izquierdo-García, Berta Montero Pastor, Ana Such Díaz, Elena Alba Álvaro-Alonso, Laura López Guerra & Ismael Escobar-Rodríguez

  2. Pharmacy Department, Hospital General Universitario Santa Lucía, Cartagena, Spain

    Andrea Lázaro-Cebas

Authors
  1. Elsa Izquierdo-García
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrea Lázaro-Cebas
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Berta Montero Pastor
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana Such Díaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Elena Alba Álvaro-Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Laura López Guerra
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ismael Escobar-Rodríguez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EIG conceived and designed the study; analysed and interpreted the data; wrote the primary manuscript; and submitted the final manuscript. ALC, BMP, ASD, EAAA, LLG and IER reviewed the manuscript and provided substantial revisions to the manuscript with contribution of important intellectual content and methodology. All authors critically reviewed the manuscript during its preparation and approved the final version.

Corresponding author

Correspondence to Elsa Izquierdo-García.

Ethics declarations

Ethics approval and consent to participate

Non applicable. The System Usability Scale in a sample of potential users is made with an anonymous online survey (Google Forms) in accordance with current data European General Data Protection Regulation, and no medical data were collected. Users were required to agree to google’s privacy policy previously to answer the survey (https://policies.google.com/privacy).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Izquierdo-García, E., Lázaro-Cebas, A., Montero Pastor, B. et al. Design of mobile and website health application devices for drug tolerability in hereditary fructose intolerance. Orphanet J Rare Dis 19, 12 (2024). https://doi.org/10.1186/s13023-023-03011-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13023-023-03011-x

Keywords

Orphanet Journal of Rare Diseases

ISSN: 1750-1172